1 |
Arikan SK, Kasap B, Yetimalar H, et al (2014). Impact of prognostic factors on survival rates in patients with ovarian carcinoma. Asian Pac J Cancer Prev, 15, 6087-94.
DOI
|
2 |
Arun-Muthuvel V, Jaya V (2014). Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound. Asian Pac J Cancer Prev, 15, 2929-32.
DOI
ScienceOn
|
3 |
Bartella L, Morris EA, Dershaw DD, et al (2006). Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiol, 239, 686-92.
DOI
ScienceOn
|
4 |
Booth SJ, Pickles MD, Turnbull LW (2009). In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla. BJOG, 116, 300-3.
DOI
|
5 |
Boyle P, Maisonneuve P, Autier P (2000). Update on cancer control in women. Int J Gynaecol Obstet, 70, 263-303.
DOI
|
6 |
Esseridou A, Di Leo G, Sconfienza LM, et al (2011). In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy. Invest Radiol, 46, 377-82.
DOI
|
7 |
Karadag B, Kocak M, Kayikcioglu F, et al (2014). Risk for malignant and borderline ovarian neoplasms following basic preoperative evaluation by ultrasonography, ca125 level and age. Asian Pac J Cancer Prev, 15, 8489-93.
DOI
|
8 |
Kunpalin Y, Triratanachat S, Tantbirojn P (2014). Proportion of ovarian cancers in overall ovarian masses in Thailand. Asian Pac J Cancer Prev, 15, 7929-34.
DOI
|
9 |
Mohaghegh P, Rockall AG (2012). Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. Radiographics, 32, 1751-73.
DOI
|
10 |
Negendank W (1992). Studies of human tumors by MRS: a review. NMR Biomed, 5, 303-24.
DOI
ScienceOn
|
11 |
Oz G, Alger JR, Barker PB, et al (2014). Clinical proton MR spectroscopy in central nervous system disorders. Radiol, 270, 658-79.
DOI
|
12 |
Ozbay PO, Ekinci T, Caltekin MD, et al (2015). Comparative evaluation of the risk of malignancy index scoring systems (1-4) used in differential diagnosis of adnexal masses. Asian Pac J Cancer Prev, 16, 345-9.
DOI
|
13 |
Simsek HS, Tokmak A, Ozgu E, et al (2014). Role of a risk of malignancy index in clinical approaches to adnexal masses. Asian Pac J Cancer Prev, 15, 7793-7.
DOI
|
14 |
Stanwell P, Russell P, Carter J, et al (2008). Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Invest Radiol, 43, 745-51.
DOI
|
15 |
Swindle P, McCredie S, Russell P, et al (2003). Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiol, 228, 144-51.
DOI
|
16 |
Takeuchi M, Matsuzaki K, Nishitani H (2010). Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr, 34, 173-6.
DOI
|
17 |
Tantipalakorn C, Wanapirak C, Khunamornpong S, et al (2014). IOTA simple rules in differentiating between benign and malignant ovarian tumors. Asian Pac J Cancer Prev, 15, 5123-6.
DOI
|
18 |
Thomassin-Naggara I, Bazot M, Darai E, et al (2008). Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiol, 248, 148-59.
DOI
|
19 |
Thomassin-Naggara I, Toussaint I, Perrot N, et al (2011). Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiol, 258, 793-803.
DOI
|